These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9456005)
1. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Rollema H; Lu Y; Schmidt AW; Zorn SH Eur J Pharmacol; 1997 Nov; 338(2):R3-5. PubMed ID: 9456005 [TBL] [Abstract][Full Text] [Related]
2. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666 [TBL] [Abstract][Full Text] [Related]
3. DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Ichikawa J; Dai J; Meltzer HY Brain Res; 2001 Jul; 907(1-2):151-5. PubMed ID: 11430898 [TBL] [Abstract][Full Text] [Related]
4. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Assié MB; Cosi C; Koek W Eur J Pharmacol; 1997 Sep; 334(2-3):141-7. PubMed ID: 9369342 [TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Ichikawa J; Li Z; Dai J; Meltzer HY Brain Res; 2002 Nov; 956(2):349-57. PubMed ID: 12445705 [TBL] [Abstract][Full Text] [Related]
6. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. Díaz-Mataix L; Scorza MC; Bortolozzi A; Toth M; Celada P; Artigas F J Neurosci; 2005 Nov; 25(47):10831-43. PubMed ID: 16306396 [TBL] [Abstract][Full Text] [Related]
7. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Li Z; Ichikawa J; Dai J; Meltzer HY Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766 [TBL] [Abstract][Full Text] [Related]
8. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Ichikawa J; Dai J; Meltzer HY Brain Res; 2002 Jun; 939(1-2):34-42. PubMed ID: 12020849 [TBL] [Abstract][Full Text] [Related]
9. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Ichikawa J; Meltzer HY Eur J Pharmacol; 1999 Sep; 380(1):R1-3. PubMed ID: 10513560 [TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Westerink BH; Kawahara Y; De Boer P; Geels C; De Vries JB; Wikström HV; Van Kalkeren A; Van Vliet B; Kruse CG; Long SK Eur J Pharmacol; 2001 Jan; 412(2):127-38. PubMed ID: 11165224 [TBL] [Abstract][Full Text] [Related]
11. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398 [TBL] [Abstract][Full Text] [Related]
12. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834 [TBL] [Abstract][Full Text] [Related]
13. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Ichikawa J; Kuroki T; Dai J; Meltzer HY Eur J Pharmacol; 1998 Jun; 351(2):163-71. PubMed ID: 9686999 [TBL] [Abstract][Full Text] [Related]
14. Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Wedzony K; Maćkowiak M; Fijał K; Gołembiowska K Eur J Pharmacol; 1996 Jun; 305(1-3):73-8. PubMed ID: 8813534 [TBL] [Abstract][Full Text] [Related]
15. AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Li Z; Bonhaus DW; Huang M; Prus AJ; Dai J; Meltzer HY Eur J Pharmacol; 2007 Oct; 572(2-3):129-37. PubMed ID: 17628522 [TBL] [Abstract][Full Text] [Related]
16. Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test. Feng M; Gao J; Sui N; Li M Psychopharmacology (Berl); 2015 Apr; 232(7):1219-30. PubMed ID: 25288514 [TBL] [Abstract][Full Text] [Related]
17. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477 [TBL] [Abstract][Full Text] [Related]
18. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514 [TBL] [Abstract][Full Text] [Related]
19. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111 [TBL] [Abstract][Full Text] [Related]
20. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. Millan MJ; Schreiber R; Dekeyne A; Rivet JM; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M J Pharmacol Exp Ther; 1998 Sep; 286(3):1356-73. PubMed ID: 9732399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]